Published on 6 Jun 2016
Valeant
Pharmaceuticals is set to release results before the bell Tuesday.
Analysts are anticipating the Botox maker to report adjusted earnings of
$1.36 a share, that's down $1 from a year ago. Revenue estimates for
this quarter are expected to grow about 8.7% to about $2.4 billion.
Tuesday is Valeant's second quarterly report since its pricing and
compliance scandals were revealed. The Fill or Kill team will be keeping
a close eye on whether or not Valeant will beat top and bottom line
estimates.. and if there is any further information on how the drug
maker plans to reduce its debt.
No comments:
Post a Comment